Cannabis Investment Quality Screen
Filter an emerging sector through quality, legality, and diversification
- Difficulty
- Advanced
- Time to result
- ~weeks to results
- Steps
- 7
- Confidence
- 93%
This screen combines conventional equity diligence with emerging-sector controls. Start with the same attributes expected from any sound company: capable management, a viable balance sheet, quality products, distribution, defensible intellectual property, and credible brands. Then account for the sector's unusual risks by verifying legal structure, exchange status, scientific competence, and exposure to policy change. Avoid assuming cultivation alone captures the opportunity; map candidates across pharmaceuticals, laboratories, extraction, consumer goods, hemp, and other verticals. Geographic diversification matters because regulation and adoption advance unevenly. The final portfolio should contain only legitimate operators, spread thematic exposure across distinct business models, and avoid directly handling activities that create unresolved federal, banking, or tax complications.
Origin
Extracted from Masters in Business, where Todd Harrison described CB1 Capital's public-equity approach to cannabinoid healthcare investing.
Core principles
- 01Treat cannabis as a multi-sector healthcare opportunity, not a single crop
- 02Apply ordinary company-quality tests before considering thematic upside
- 03Separate legitimate operators from promotional listings
- 04Diversify across geographies and industry verticals
- 05Avoid activities that create unacceptable legal or tax exposure
How to run it
- 1
Define the investable theme
Specify whether the thesis concerns medicine, ingredients, consumer products, industrial uses, or another vertical. Do not collapse the whole industry into cultivation.
Pro tip Map the value chain before reviewing individual tickers.
Watch out A broad legalization narrative is not sufficient company-level diligence.
- 2
Remove illegitimate candidates
Exclude promotional, legally questionable, or poorly governed listings before comparing upside. Confirm that the company is publicly traded on an exchange and understand whether it touches regulated products directly.
Pro tip Use governance and legal status as gates rather than weighted preferences.
Watch out Low prices and exciting claims do not compensate for legitimacy risk.
- 3
Apply core company tests
Evaluate management, balance sheet, brands, distribution, product quality, and other fundamentals appropriate to the business model.
Pro tip Compare each candidate with mature companies in the same functional vertical.
Watch out Do not suspend ordinary valuation and quality standards because the sector is new.
- 4
Assess defensibility
Identify patents, scientific expertise, proprietary formulations, regulatory progress, or distribution advantages that competitors cannot quickly reproduce.
Pro tip For biopharmaceutical candidates, distinguish clinical validation from anecdotal evidence.
Watch out Cultivation capacity by itself may become commoditized as supply expands.
- 5
Map policy and geographic exposure
Determine which jurisdictions drive revenue, research, banking access, and future growth. Examine how policy changes could affect each exposure.
Pro tip Favor a mix of jurisdictions moving through different adoption stages.
Watch out Do not assume one country's regulatory model will transfer directly to another.
- 6
Construct across verticals
Spread qualified holdings across distinct parts of the value chain rather than concentrating on one popular category.
Pro tip Include picks-and-shovels businesses when their economics are less dependent on a single product outcome.
Watch out Multiple cultivators can still represent one concentrated risk.
- 7
Size for uncertainty
Treat the portfolio as speculative healthcare exposure and size it according to liquidity, evidence, and downside risk.
Pro tip Reserve capital for later clinical, regulatory, or institutional confirmation.
Watch out Nascent-sector volatility can overwhelm an otherwise sound long-term thesis.
In the wild
An investor confirms that a candidate is exchange-listed, has experienced pharmaceutical management, sufficient cash for upcoming trials, a defensible patent portfolio, and published clinical work. Because the company depends on one trial and one jurisdiction, it receives a smaller allocation alongside laboratory and ingredient businesses in other markets.
→ The portfolio captures scientific upside without treating a single clinical result as the entire theme.
A low-priced cultivator advertises huge planned capacity but has weak governance, recurring dilution, no distribution advantage, and no clear path to profitability. The investor rejects it despite bullish sector forecasts.
→ The screen prevents a thematic narrative from overriding company-quality failures.
Common mistakes
Treating cultivation as the whole market
Growing capacity can become commoditized as supply expands. Durable value may accrue to medicine, brands, extraction, laboratories, and other verticals.
Buying every listed company
A nascent market attracts weak and promotional operators. Legitimacy and governance must be established before upside is considered.
Ignoring jurisdictional risk
Research rules, banking access, taxation, and medical distribution differ sharply by country and state. A sound product can still be impaired by its operating environment.
Is it for you?
Best for
Experienced investors evaluating publicly traded companies in a nascent, fragmented, and regulation-sensitive industry.
Not ideal for
It is not ideal for investors unable to tolerate volatility, conduct specialist research, or absorb a complete loss.
From the transcript
“you're looking for brands, and you're looking for brands at a distribution and quality of product, and certainly good management teams and all the things…”
“Right you're looking at management teams, you're looking at at their balance sheet, you're looking at their patent portfolio, whatever the case may be.”
“we're looking across ten verticals, which includes cultivation dispensaries, but certainly we think that's gonna migrate to drugs.”
From the episode
Todd Harrison Discusses Biopharmaceutical Investments
Todd Harrison